Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Non-Current Assets (2016 - 2025)

Arcadia Biosciences' Non-Current Assets history spans 12 years, with the latest figure at $190000.0 for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 95.56% year-over-year to $190000.0; the TTM value through Dec 2025 reached $4.7 million, down 73.88%, while the annual FY2025 figure was $190000.0, 95.56% down from the prior year.
  • Non-Current Assets reached $190000.0 in Q4 2025 per RKDA's latest filing, down from $197000.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $19.9 million in Q2 2021 to a low of $190000.0 in Q4 2025.
  • Average Non-Current Assets over 5 years is $5.8 million, with a median of $4.4 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: surged 70.19% in 2021, then tumbled 95.76% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $8.5 million in 2021, then plummeted by 58.69% to $3.5 million in 2022, then soared by 34.31% to $4.7 million in 2023, then dropped by 9.68% to $4.3 million in 2024, then crashed by 95.56% to $190000.0 in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Non-Current Assets are $190000.0 (Q4 2025), $197000.0 (Q3 2025), and $209000.0 (Q2 2025).